Human Vaccines & Immunotherapeutics最新文献

{"title":"Waning immunity and the future of booster vaccination strategies in global vaccine programs post COVID-19.","authors":"Rhitam Biswas, Aditi Roy, Titirsha Kayal, Soumya Basu, Soumyadip Ghosh, Sudha Ramaiah, Anand Anbarasu","doi":"10.1080/21645515.2026.2626088","DOIUrl":"10.1080/21645515.2026.2626088","url":null,"abstract":"<p><p>The problem of waning immunity is a major global concern of vaccine programs, with immunity against diseases such as COVID-19 (reduction in efficacy by ~25% in six months), pertussis (waning in 4-12 y), and influenza (annual updates needed) expected to decrease with time. While boosters reduce serious results in high-risk categories, these effects are short-term (4-6 months) and encourage global imbalances, where low-income areas lag in primary vaccination (<2%). Computational models have shown that primary vaccination in underserved regions prevents ~60% of hospitalizations worldwide, surpassing booster-focused measures (~47%). To maintain protection, variant-responsive boosters, rapid booster-design pipelines, universal vaccine platforms (including pan-coronavirus vaccines), and equity-based solutions (decentralized production) need to be integrated. Aligning with frameworks like the Immunization Agenda 2030 of the World Health Organization, plans should balance the expansion of high-risk groups while broadening primary access, providing infrastructure investment, and real-time surveillance to address evolving pathogens and systemic disparities.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2626088"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12893694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146144333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acceptance and the willingness to pay for human papilloma virus (HPV) vaccine: A systematic review.","authors":"Soheila Rajaie, Sara Emamgholipour, Samad Azari, Zeinab Karimi, Fereshte Karimi","doi":"10.1080/21645515.2025.2609345","DOIUrl":"10.1080/21645515.2025.2609345","url":null,"abstract":"<p><p>Human papillomavirus (HPV) is a major global health concern due to its link to cervical and other cancers. Although HPV vaccination is highly effective, acceptance and willingness to pay (WTP) differ widely across populations. This review summarizes global evidence from 2015-2025. A systematic search of PubMed, Scopus, CENTRAL, Web of Science, and Google Scholar was conducted in 2025 following PRISMA guidelines. Studies reporting data on knowledge, acceptance, attitudes, and WTP across any population were included. Quality assessment used ISPOR checklists, and data were synthesized in Excel 2019. Thirty-five studies met inclusion criteria, with China and Nigeria contributing most. WTP ranged from 52.68% in lower-middle-income countries to 65.38% in low-income countries. Mean WTP was highest in upper-middle-income settings. Knowledge, positive attitudes, socioeconomic status, and trust increased WTP, while cost remained the primary barrier. Improving affordability, awareness, and policy support is essential to enhance global HPV.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2609345"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/21645515.2026.2694263","DOIUrl":"10.1080/21645515.2026.2694263","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2694263"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148399794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with vaccination intentions and uptake among pregnant women in the UK: A scoping review.","authors":"Mohammed Khudair, Stephanie L Swift, Kimberly Dienes, Yumitra A Kannan, Kavita Vedhara","doi":"10.1080/21645515.2026.2687220","DOIUrl":"10.1080/21645515.2026.2687220","url":null,"abstract":"<p><p>This scoping review aimed to identify factors associated with vaccination decisions among pregnant women in the UK, guided by the SAGE matrix on vaccine hesitancy, and explored differences between qualitative and quantitative findings and between vaccine intentions (attitudes) and actual uptake (behaviors). Embase®, MEDLINE®, PsycInfo, Web of Science, and Cochrane were searched; rapid review methodologies were applied. From 2,326 records, 49 primary studies were included (published 2010-2025). We identified 222 qualitative factors from 32 studies, and 114 quantitative factors from 30 studies. Qualitative studies frequently reported individual and group influences, particularly beliefs and attitudes about vaccine effectiveness and safety, and the role of healthcare professionals in decision-making. Quantitative studies highlighted sociodemographic influences, including older age, ethnicity, and lower social/economic deprivation. Factors found to be associated with vaccination intention vs. uptake were inconsistent, though these findings should be interpreted cautiously given the modest number of studies addressing this issue.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2687220"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148303697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine hesitancy and attitudes toward newborn heel-prick screening among religious officials: A mixed-methods study, Erzurum, Türkiye.","authors":"Esra Daharli, Ertuğrul Çoruh","doi":"10.1080/21645515.2026.2684831","DOIUrl":"10.1080/21645515.2026.2684831","url":null,"abstract":"<p><p>Vaccine hesitancy has risen globally and in Türkiye. Religious officials often act as community opinion leaders; their views may shape acceptance of vaccination and newborn bloodspot screening (NBS). We conducted a cross-sectional study among Muslim religious officials in Erzurum, Türkiye (n = 200). A 47-item questionnaire captured sociodemographics, health-service use/satisfaction, attitudes to childhood/adult vaccines and newborn bloodspot screening, and the 21-item Turkish Vaccine Hesitancy Scale (higher scores = higher hesitancy). Open-ended item elicited qualitative comments. Quantitative comparisons used t-tests/one-way ANOVA (α = 0.05). Qualitative data underwent inductive thematic analysis (Braun-Clarke); two independent coders achieved Cohen's κ = 0.80. Mean vaccine hesitancy score was 62.9 ± 11.4. Scores did not differ by sociodemographics (p > .05). Lower satisfaction with health services was associated with higher hesitancy (overall p = .004). Hesitancy varied by attitudes toward adult vaccination (p = .003), childhood vaccination (p = .002), and NBS support (p = .004) - with lower scores among supporters. Only 19% were aware of the Organization of Islamic Cooperation (OIC) fatwa on vaccination; awareness was not associated with hesitancy (p > .05). Thematic analysis (n = 40 textual responses) yielded five themes: safety/adverse-effect concerns (27.5%); information & service-process experience (22.5%); perceived benefit/effectiveness (bipolar) (20.0%); privacy/biomaterial (NBS) (17.5%); and fertility/genetic-harm beliefs (12.5%).Among religious officials, vaccine hesitancy appeared to cluster around safety and institutional trust, reinforced by privacy/biomaterial, fertility/genetic, and effectiveness narratives. Interventions should prioritize content transparency (including halal and safety information), process transparency for NBS (storage/secondary use/disposal policies), co-delivery of messages by physicians and religious officials, proactive risk communication, and brief, targeted training modules.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2684831"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13245093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test.","authors":"Tao Luan, Suneng Fu, Weiting Liu, Shuaiying Wang, Xiaohong Xie, Xinqing Lin, Zekun Chenli, Liqiang Wang, Kangjing Ma, Hongbin Ma, Junyi Mo, Baodan Yu, Qingqing Yang, Yilin Xu, Hui Jin, Qishan Chen, Leyang Yao, Yang Luan, Nanshan Zhong, Qun Lv, Yunhui Zhang, Chengzhi Zhou","doi":"10.1080/21645515.2026.2629081","DOIUrl":"10.1080/21645515.2026.2629081","url":null,"abstract":"<p><p>Human Epidermal Growth Factor Receptor 2 (HER2) mutations account for approximately 3% of non-small cell lung cancer (NSCLC) patients. Currently, targeted therapies for HER2-mutant NSCLC include HER2 tyrosine kinase inhibitors (TKIs) and HER2 Antibody-drug conjugates (ADC). However, resistance often develops, and effective treatments for HER2 mutations remain lacking. We report a case of HER2-mutant lung adenocarcinoma where the patient developed resistance and severe interstitial lung disease following antibody-drug conjugate therapy. A highly biomimetic Human Organoid (HO) platform was employed to screen potential therapeutic options for the patient. The HO results indicated efficacy of Sunvozertinib and ineffectiveness of ADC, with maximum half-maximal inhibitory concentration (IC₅₀) values of 0.28 and 2.96, respectively. This case demonstrates the potential of Human Organoid Drug Sensitivity Test (HO-DST) to guide effective salvage therapy, bridging the gap between genomic profiling and functional drug response in precision oncology.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2629081"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12915762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report.","authors":"Zipei Chen, Qiongshan Chen, Yihan Zhuang, Wen Lin","doi":"10.1080/21645515.2025.2608408","DOIUrl":"10.1080/21645515.2025.2608408","url":null,"abstract":"<p><p>Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2608408"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13089929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147693095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion on improving influenza vaccination coverage rate in Qatar: Strategic solutions and role of live attenuated influenza vaccine (LAIV).","authors":"Muna Al-Maslamani, George Kassianos, Khalid El Awad, Eman Al Maslamani, Mohammed Alkuwari, Salah Al Awaidy, Peter V Coyle, Manasik Hassan, Hayat S Khogali, Samina Hasnain, Hadi M Yassine, Ahmed Abushahin","doi":"10.1080/21645515.2026.2628383","DOIUrl":"10.1080/21645515.2026.2628383","url":null,"abstract":"<p><p>Seasonal influenza remains a major public health challenge in Qatar, causing significant morbidity and mortality among high-risk groups. Despite annual campaigns and free vaccines, coverage-rate is low, especially among children, the elderly, and pregnant women. This expert opinion review highlights vaccine-related epidemiological trends and barriers to uptake, including hesitancy, limited public awareness, logistical issues, and gaps in healthcare provider education in Qatar region. The panel underscores the urgent need for robust public education, targeted outreach, and empowering healthcare professionals to improve vaccine uptake. Special emphasis is placed on the role of live-attenuated-influenza-vaccine (LAIV), which allows needle-free administration, enhanced immunogenicity, and is suitable for school-based programs. Recommendations include expanding access via mobile clinics and schools, aligning procurement with seasonal peaks, and strengthening surveillance and quality systems. Adopting these strategies and empowering healthcare providers with necessary tools and knowledge can significantly improve influenza vaccination-coverage in Qatar and reinforce long-term public health resilience.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2628383"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12915769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146183274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents.","authors":"Olajide J Olagunju, Oladayo A Oyebanji, Debbie Keresztesy, Dennis Wilk, Evan Dickerson, Tiffany Wallace, Laurel Holland, Mike Payne, Ellen See, Chia Jung Li, Eunice Lim, Yasin Abul, Clare Nugent, Alejandro B Balazs, Jürgen Bosch, Christopher L King, Brigid Wilson, Stefan Gravenstein, David H Canaday","doi":"10.1080/21645515.2026.2705661","DOIUrl":"10.1080/21645515.2026.2705661","url":null,"abstract":"<p><p>Nursing home residents (NHRs) remain among the most vulnerable to severe outcomes from SARS-CoV-2 infection. While mRNA-1273 (Spikevax, Moderna) and BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccines are widely used in this population, comparative data on their immunogenicity, particularly after bivalent boosters, remain limited. We conducted a longitudinal immunologic evaluation of U.S. NHRs who received either the mRNA-1273 or BNT162b2 bivalent vaccine. Serum samples were collected 10-30 d post-vaccination. Anti-spike IgG levels were measured using a Luminex bead-based assay, and neutralizing titers were assessed via pseudovirus neutralization. Comparative analyses of the titer distributions were performed using two-sided Wilcoxon rank-sum tests. Both vaccine groups demonstrated strong humoral responses to the ancestral Wuhan strain and Omicron BA.4/5 subvariants. Spike-binding antibody levels and neutralization titers were comparable between the mRNA -1273 and BNT162b2 vaccine formulations. Conclusions: Both mRNA-1273 and BNT162b2 mRNA vaccines elicit similarly robust humoral immunity in NHRs, supporting their interchangeable use in booster strategies. Our findings underscore the importance of timely booster administration over exact product selection in protecting this high-risk, immunosenescent population.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2705661"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13471111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research trends and hotspots of CAR-T cell therapy for acute lymphoblastic leukemia: A bibliometric analysis.","authors":"Xiaolong Tian, Yingping Zhang, Chen Zhang, Dongdong Liu, Yanmin Ma","doi":"10.1080/21645515.2026.2690723","DOIUrl":"10.1080/21645515.2026.2690723","url":null,"abstract":"<p><p>This study aims to analyze the global research patterns and emerging trends in CAR-T cell therapy for ALL through a bibliometric analysis. Publications were retrieved from the Web of Science Core Collection database. The bibliometric analysis utilized VOSviewer, CiteSpace, and the R package \"bibliometrix\" to visualize collaborations, keyword co-occurrences, and emerging research trends. A total of 844 articles from 253 journals by 6,459 authors across 44 countries were analyzed, showing an annual growth rate of 40.08%. The USA (372 articles, 38,065 citations) and China (275 articles, 5,636 citations) dominated research output. The University of Pennsylvania (353 articles), Memorial Sloan Kettering Cancer Center (170), and Children's Hospital of Philadelphia (131) were the most productive institutions, while <i>Blood</i> (41 articles) published the most articles. Stephan A. Grupp (38 articles, H-index = 30), Carl H. June (26 articles, H-index = 24), and Shannon L. Maude (25 articles, H-index = 20) were the most influential authors. Keyword analysis revealed five research clusters, including basic mechanisms, CAR design, population treatment integration, clinical outcomes, and toxicity management. Burst keyword analysis showed the evolution from basic science (2010-2013) to clinical translation (2014-2016), toxicity management (2017-2019), and recently to long-term outcomes and risk assessment (2020-2024), with \"term follow-up\" and \"risk\" as the only keywords with active bursts in 2024. This bibliometric analysis reveals that research on CAR-T therapy for ALL has progressed from foundational concepts to clinical implementation and now focuses on optimizing long-term outcomes and patient selection. Future research should prioritize biomarker development, next-generation CAR designs, and combination strategies to overcome persistence, toxicity, and resistance limitations in ALL treatment.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2690723"},"PeriodicalIF":4.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}